We are live on ! Find out more
RP

Regeneron Pharmaceuticals Portfolio holdings

AUM $177M
1-Year Est. Return 9.82%
This Fund
S&P 500
This Quarter Est. Return
+2.77%
1 Year Est. Return
+9.82%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$177M
AUM Growth
+$129M
Cap. Flow
+$115M
Cap. Flow %
64.95%
Top 10 Hldgs %
100%
Holding
3
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
PBLS
Parabilis Medicines Inc
PBLS
+$115M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PBLS
1
Parabilis Medicines Inc
PBLS
$4.85B
$114M 64.35%
+4,166,666
New +$115M
NTLA icon
2
Intellia Therapeutics
NTLA
$1.84B
$62.7M 35.35%
3,702,995
– –
ACET icon
3
Adicet Bio
ACET
$84.3M
$523K 0.3%
60,511
– –

Similar funds

SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
MSA
Marathon Strategic Advisors Pittsburgh, Pennsylvania $177M AUM 66.85% 1-Year Est. Return
HF
Holcombe Financial Atlanta, Georgia $177M AUM 13.35% 1-Year Est. Return
CWP
Clark Wealth Partners O'fallon, Illinois $177M AUM 22.36% 1-Year Est. Return
BFAG
Blackston Financial Advisory Group The Villages, Florida $177M AUM 21.44% 1-Year Est. Return
WFG
Wormser Freres Gestion Paris, France $177M AUM 13.84% 1-Year Est. Return
AAS
AdviceOne Advisory Services Glastonbury, Connecticut $177M AUM 26.65% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

Regeneron Pharmaceuticals's Q2 2026 Portfolio in Review

As of Q2 2026, Regeneron Pharmaceuticals held 3 positions worth $177M, up 270% from $47.9M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Regeneron Pharmaceuticals deployed $115M of net new capital in Q2 2026, opening 1 new position. Its largest new stake was Parabilis Medicines Inc: 4,166,666 shares worth $114M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Regeneron Pharmaceuticals's largest Q2 2026 buy was Parabilis Medicines Inc: 4,166,666 shares worth $114M.
  • Regeneron Pharmaceuticals's ten largest holdings make up 100% of its $177M portfolio in Q2 2026.
  • Regeneron Pharmaceuticals opened 1 new position and closed 0 in Q2 2026.
  • Regeneron Pharmaceuticals's portfolio value rose 270% quarter-over-quarter to $177M.

Based on Regeneron Pharmaceuticals's 13F filing for Q2 2026, filed 7 Aug 2026.